Compare DDS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDS | IBRX |
|---|---|---|
| Founded | 1938 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 8.4B |
| IPO Year | N/A | 2015 |
| Metric | DDS | IBRX |
|---|---|---|
| Price | $599.28 | $8.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $519.67 | $12.57 |
| AVG Volume (30 Days) | 113.2K | ★ 28.4M |
| Earning Date | 02-24-2026 | 02-23-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $1.06 | $88.57 |
| Revenue Next Year | $2.02 | $146.98 |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $282.24 | $1.83 |
| 52 Week High | $741.98 | $12.43 |
| Indicator | DDS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 55.55 |
| Support Level | $586.59 | $2.27 |
| Resistance Level | $634.02 | $12.43 |
| Average True Range (ATR) | 23.88 | 0.70 |
| MACD | -0.08 | -0.20 |
| Stochastic Oscillator | 51.09 | 30.00 |
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.